COVID-19 vaccines available in the United States^[1-6]

Name	Platform	Indicated ages	Dose	WITHOUT moderate to severe immunocompromising condition	WITH moderate to severe immunocompromising condition	Common side effects
Moderna COVID-19 vaccine (2023-2024 Formula)	mRNA	6 months through 4 years	25 mcg (0.25 mL dark blue-capped vial)	For individuals not previously vaccinated with any COVID-19 vaccine^*: Two vaccine doses 4 to 8 weeks apart^¶	For individuals not previously vaccinated with any COVID-19 vaccine^*: Three vaccine doses: First two given 4 weeks apart Third given at least 4 weeks after the second	Local injection site reactions Systemic symptoms (fevers, chills, fatigue, myalgias, headache)
		5 through 11 years	25 mcg dose (0.25 mL dark blue-capped vial)	For all immunocompetent individuals in these age groups: Single vaccine dose (if previously vaccinated, give at least 8 weeks after last dose)
		12 years and older	50 mcg (0.5 mL)
Pfizer/BioNTech COVID-19 vaccine (2023-2024 Formula)	mRNA	6 months through 4 years^Δ	3 mcg (0.3 mL yellow-capped vial)	For individuals not previously vaccinated with any COVID-19 vaccine^*: Three vaccine doses: First two given 3 to 8 weeks apart^¶ Third given at least 8 weeks after the second	For individuals not previously vaccinated with any COVID-19 vaccine^*: Three vaccine doses: First two given 3 weeks apart Third given at least 8 weeks after the second	Local injection site reactions Systemic symptoms (fevers, chills, fatigue, myalgias, headache)
		5 through 11 years	10 mcg (0.3 mL blue-capped vial)	For all immunocompetent individuals in these age groups: Single vaccine dose (if previously vaccinated, give at least 8 weeks after last dose)	For individuals not previously vaccinated with any COVID-19 vaccine^*: Three vaccine doses: First two given 3 weeks apart Third given at least 4 weeks after the second
		12 years and older	30 mcg (0.3 mL)
Novavax COVID-19 vaccine (2023-2024 Formula)	Recombinant protein, adjuvanted	12 years and older	5 mcg spike protein/50 mcg adjuvant doses (0.5 mL)	For individuals not previously vaccinated with any COVID-19 vaccine: Two vaccine doses 3 to 8 weeks apart^¶ For individuals who have received at least one prior COVID-19 vaccine dose (but not an updated 2023-2024 formula): Single vaccine dose at least 2 months after last dose		Local injection site reactions Systemic symptoms (fevers, chills, fatigue, myalgias, headache)

We recommend vaccination with one of these vaccines for eligible individuals. Updated mRNA vaccines (Moderna COVID-19, 2023-2024 formula and Pfizer-BioNTech COVID-19 vaccine, 2023-2024 formula) are recommended for all vaccine doses. For individuals who cannot or will not take an mRNA vaccine, the updated Novavax COVID-19 vaccine is an alternative.

CDC: Centers for Disease Control and Prevention; COVID-19: coronavirus disease 2019.

* For individuals younger than five years of age and individuals with moderately to severely immunocompromising conditions who have already received previous vaccine doses, recommendations on updated vaccine doses depend on the number of prior vaccines received. If they have received at least three mRNA vaccine doses, the updated vaccine should be given at least eight weeks after the most recent dose. Refer to other UpToDate content for details.

¶ Although the FDA authorized intervals for the second doses of the Moderna, Novavax, and Pfizer COVID-19 bivalent vaccines are four, three, and three weeks after the first dose, respectively, the CDC suggests an interval up to eight weeks. Extending the interval to eight weeks between vaccine doses may be preferable for those (especially males aged 12 to 39 years) who have no major comorbidities and do not need to maximize protection within a shorter period of time; longer intervals may be associated with a lower risk of myocarditis and slightly improved effectiveness.^[5]

Δ Children who turn five years of age during the series should receive all three doses with the formulation and dose recommended for children six months through four years.

References:

SPIKEVAX (COVID-19 Vaccine, mRNA) Suspension for injection, for intramuscular use; 2023-2024 Formula. US Food and Drug Administration (FDA) approved product information. Revised September 11, 2023. Available at: https://www.fda.gov/media/155675/download?attachment (Accessed on September 11, 2023).
Fact sheet for healthcare providers administering vaccine: Emergency use authorization of Moderna COVID-19 vaccine (2023-2024 formula), for individuals 6 months through 11 years of age. Available at: https://www.fda.gov/media/167208/download?attachment (Accessed on September 11, 2023).
COMIRNATY (COVID-19 Vaccine, mRNA) suspension for injection, for intramuscular use; 2023-2024 Formula. US Food and Drug Administration (FDA) approved product information. Revised September 11, 2023. Available at: https://www.fda.gov/media/151707/download?attachment (Accessed on September 11, 2023).
Fact sheet for healthcare providers administering vaccine: Emergency use authorization of Pfizer-Biontech COVID-19 vaccine (2023-2024 formula), for 6 months through 11 years of age. Available at: https://www.fda.gov/media/167211/download?attachment (Accessed on September 11, 2023).
Centers for Disease Control and Prevention. Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States. Available at: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html (Accessed on September 17, 2023).
US Food and Drug Administration. Emergency use authorization (EUA) of the Novavax COVID-19 vaccine, adjuvanted (2023-2024 formula), for individuals 12 years or older. Available at: https://www.fda.gov/media/159897/download (Accessed on October 4, 2023).

Graphic 130711 Version 49.0

خرید پکیج

COVID-19 vaccines available in the United States[1-6]

COVID-19 vaccines available in the United States^[1-6]